Mobilization and Collection of Peripheral Blood Stem Cells in Adults: Focus on Timing and Benchmarking

Kriegsmann, Katharina; Wuchter, Patrick

doi:10.1007/978-1-4939-9574-5_4

Cited by 3 publications

(2 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-emptive use, also known as 'rescue' or 'just in time use', refers to the introduction of plerixafor in the course of a mobilization episode in order to improve the collection of HPCs and is usually guided by the scarce number of CD34+ cells circulating in PB before starting leukocytapheresis (usually <10,000 cells/ml) [44,45]. Up front and pre-emptive use rely on the prediction of a poor mobilization.…”

Section: How Is Plerixafor Used? Dosing and Administrationmentioning

confidence: 99%

“…However, in the allogeneic setting, apheresis procedures should be planned, customized and performed on the day of maximum CD34+ cell count in PB to maximize HPC yield. Facilities performing apheresis should know their collection efficiency and should use the best-suited apheresis protocols to tailor the process to the expected CD34+ cell yield, thus reducing the number of apheresis procedures needed and minimizing inconvenience and adverse effects to the donor [13,44,54]. Bartnik et al in a series of 80 donors found that continuous mononuclear collection protocol using a Spectra Optia platform (TerumoBCT, Leuven, Belgium) impacted favourably in donors with negative collection predictors [57].…”

Section: How Is Plerixafor Used? Dosing and Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

et al. 2021

View full text Add to dashboard Cite

Increased transplant activity calls for improved stem cell collection, especially when peripheral blood is the preferred source of haematopoietic progenitor cells (HPCs).Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4-CXCL12-supported HPC retention. Plerixafor is given with granulocyte colony-stimulating factor (G-CSF) to help harvest autologous CD34+ cells for transplantation when mobilization with G-CSF fails. Mobilization protocols with the same doses of plerixafor and G-CSF have been used off-label in healthy allogeneic donors, with equal success and scarce side effects, both in adult and paediatric patients.Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G-CSF might lead to harvesting distinct cellular populations conferring improved engraftment properties and increased survival. Those characteristics might make plerixafor an especially attractive mobilization agent, particularly for non-related donations. However, available data are limited, and long-term follow-up is needed to clarify the best scenario for using plerixafor with or without G-CSF in healthy donors.In this review, we will summarize the evidence supporting this practice, highlighting the practical aspects and providing clues for an expanded use of plerixafor.

show abstract

Section: How Is Plerixafor Used? Dosing and Administrationmentioning

confidence: 99%

Section: How Is Plerixafor Used? Dosing and Administrationmentioning

confidence: 99%

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

et al. 2021

View full text Add to dashboard Cite

show abstract

Collection of Hematopoietic Stem Cells and Cell Therapy Products

Maitta

2024

Comprehensive Hematology and Stem Cell Research

View full text Add to dashboard Cite

<p>Role of Stem-Cell Transplantation in Leukemia Treatment</p>

Dessie¹,

Molla²,

Shibabaw³

et al. 2020

SCCAA

View full text Add to dashboard Cite

Stem cells (SCs) play a major role in advanced fields of regenerative medicine and other research areas. They are involved in the regeneration of damaged tissue or cells, due to their self-renewal characteristics. Tissue or cells can be damaged through a variety of diseases, including hematologic and nonhematologic malignancies. In regard to this, stem-cell transplantation is a cellular therapeutic approach to restore those impaired cells, tissue, or organs. SCs have a therapeutic potential in the application of stem-cell transplantation. Research has been focused mainly on the application of hematopoietic SCs for transplantation. Cord blood cells and human leukocyte antigen–haploidentical donors are considered optional sources of hematopoietic stem–cell transplantation. On the other hand, pluripotent embryonic SCs and induced pluripotent SCs hold promise for advancement of stem-cell transplantation. In addition, nonhematopoietic mesenchymal SCs play their own significant role as a functional bone-marrow niche and in the management of graft-vs-host disease effects during the posttransplantation process. In this review, the role of different types of SCs is presented with regard to their application in SC transplantation. In addition to this, the therapeutic value of autologous and allogeneic hematopoietic stem–cell transplantation is assessed with respect to different types of leukemia. Highly advanced and progressive scientific research has focused on the application of stem-cell transplantation on specific leukemia types. We evaluated and compared the therapeutic potential of SC transplantation with various forms of leukemia. This review aimed to focus on the application of SCs in the treatment of leukemia.

show abstract

Mobilization and Collection of Peripheral Blood Stem Cells in Adults: Focus on Timing and Benchmarking

Cited by 3 publications

References 114 publications

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

Collection of Hematopoietic Stem Cells and Cell Therapy Products

<p>Role of Stem-Cell Transplantation in Leukemia Treatment</p>

Contact Info

Product

Resources

About